If this SPL contains inactivated NDCs detailed via the FDA initiated compliance motion, they will be specified as a result.Phenobarbital is contraindicated in individuals who will be hypersensitive to barbiturates, in patients using a history of manifest or latent porphyria, and in individuals with marked impairment of liver purpose or respiratory